<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03866668</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-44589</org_study_id>
    <nct_id>NCT03866668</nct_id>
  </id_info>
  <brief_title>A Study of Esomeprazole in Children With Autism</brief_title>
  <official_title>An Open-Label Pilot Study of Esomeprazole in Children With Autism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SPARK (Stanford University)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autism is a pervasive developmental disorder characterized by core deficits in social
      behavior and communication and the presence of repetitive/stereotyped behaviors. The
      objective of the study is to evaluate the efficacy of Esomeprazole as a treatment for social
      communication deficits in children with Autism Spectrum Disorder (ASD). This prospective 12
      week open-label study will invite 25 children with ASD between the ages of 2 and 6 years of
      age to participate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline on the Social Responsiveness Scale, 2nd Edition (SRS-2)</measure>
    <time_frame>Baseline, 4 Weeks, 8 Weeks</time_frame>
    <description>Social Responsiveness Scale (SRS) raw scores measure social abilities with lower raw scores meaning better social abilities. (Raw Score Range: 0 - 195)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Aberrant Behavior Checklist, 2nd Edition (ABC-2)</measure>
    <time_frame>Baseline, 4 Weeks, 8 Weeks</time_frame>
    <description>Higher scores indicate more symptoms, lower scores indicate fewer symptoms. Irritability scores can range from 0-45. Lethargy scores can range from 0-48. Stereotypy scores can range from 0-21. Hyperactivity scores can range from 0-48. Inappropriate speech scores can from 0-12.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline on the Short Sensory Profile Questionnaire (SSPQ)</measure>
    <time_frame>Baseline, 4 Weeks, 8 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline on the Repetitive Behavoiors Scale- Revised (RBS-R)</measure>
    <time_frame>Baseline, 4 Weeks, 8 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline on the Stanford Social Motivation Scale (SSMS)</measure>
    <time_frame>Baseline, 4 Weeks, 8 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline on the Vineland Adaptive Behavoir Scales - 3 (VABS-3)</measure>
    <time_frame>Baseline, 4 Weeks, 8 Weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Autism</condition>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Esomeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks</description>
    <arm_group_label>Esomeprazole</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  outpatients 2 to 6 years of age;

          -  males and females who are physically healthy;

          -  diagnosis of autism spectrum disorder based on clinical evaluation and DSM-5 criteria,
             and confirmed using the Autism Diagnostic Interview-Revised, and the Autism Diagnostic
             Observation Schedule;

          -  care provider who could reliably bring subject to clinic visits, could provide
             trustworthy ratings, and interacted with subject on a regular basis;

          -  ability of subject to swallow the compound;

          -  stable concomitant medications for at least 2 weeks (4 weeks if patient took
             fluoxetine);

          -  no planned changes in psychosocial interventions during the open-label trial.

        Exclusion Criteria:

          -  DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder not
             otherwise specified;

          -  prior adequate trial of Esomeprazole;

          -  active medical problems such as unstable seizures, or significant physical illness
             (e.g., serious liver or renal pathology).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Hardan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lakshmi Vrittamani</last_name>
    <phone>(650) 736-1235</phone>
    <email>vrittama@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robin Libove</last_name>
    <phone>(650) 736-1235</phone>
    <email>rlibove@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lakshmi Vrittamani</last_name>
      <phone>650-736-1235</phone>
      <email>vrittama@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robin Libove</last_name>
      <phone>(650)736-1235</phone>
      <email>rlibove@stanford.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Antonio Hardan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Esomeprazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

